BioSpace News Archive

Future Pak, LLC and its affiliates announced that it has submitted a final attempt to engage with Vanda Pharmaceuticals Inc. in a good faith effort to acquire all outstanding shares of Vanda.

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - June 12, 2024) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCD) (“BioHarvest” or the “Company”), a company pioneering its patented Botanical Synthesis technology platform, today announced that management has been invited to present at the Sidoti Small-Cap Investor Conference, being held June 12-13, 2024.

Neuronetics, Inc., a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced their participation at the 12th Annual Meeting of the Clinical TMS Society in London, England from June 13th-15th.

Toronto, Ontario--(Newsfile Corp. - June 13, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on the...

Aphaia Pharma announced that it has completed enrollment in the second arm of its Phase 2 trial, which is evaluating the safety and efficacy of two separate doses of Aphaia’s formulation, or their respective placebos, twice per day to induce weight loss in individuals with obesity.

Replimune Group, Inc. announced that it has entered into a securities purchase agreement for a private investment in public equity that is expected to result in gross proceeds of approximately $100 million to the Company before deducting placement agent fees and offering expenses.

ChromaDex Corp., the global authority on nicotinamide adenine dinucleotide research and its application to healthy aging, unveils Niagen+, the first-of-its-kind pharmaceutical-grade Niagen®.

Nancy, France, June 11, 2024 - Banook Group, global provider of technology and services for clinical trial operators, today announces two strategic acquisitions that enhance its offerings in central imaging and eCOA.

Collegium Pharmaceutical, Inc., a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, announced that the U.S. Food and Drug Administration has granted pediatric exclusivity for Nucynta® and Nucynta® ER.

Umoja Biopharma, Inc. announced that pre-clinical non-human primate data on its VivoVec in vivo CAR T delivery system was published in Blood, the flagship journal of the American Society of Hematology.